Aminopyrine

Summary

Aminopyrine (CHEMBL288470) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC N02BB73); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02BB73 (+2 more)
• Indications: 2 conditions
• Chemistry: 231.29 Da · C13H17N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL288470
Name	Aminopyrine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6009
ChEBI	CHEBI:160246
ATC	N02BB73, N02BB03, N02BB53
Molecular formula	C13H17N3O
Molecular weight	231.29
InChIKey	RMMXTBMQSGEXHJ-UHFFFAOYSA-N

SMILES: CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C

IUPAC name: 4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one

ChEBI definition: A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, antipyretic.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Amidazophene, Amidopyrazoline, Aminofenazona, Aminophenazone, Aminopyrine, Brufaneuxol, Dereuma, Febron, Itamidone, Mamallet a, Netsusarin, NSC-4993

Parent form; salt/anhydrous children: CHEMBL2104635

Patent coverage: 2,959 distinct patent families (8,254 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Prelamin-A/C, Ferritin light chain, Thyroid hormone receptor beta, Thyrotropin receptor, Polyunsaturated fatty acid lipoxygenase ALOX15, Cytochrome P450 1A2, Nicotinate phosphoribosyltransferase.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NAPRT	9	Ki	1	nM	CHEMBL_ACT_19323238
LMNA	7.2	Potency	63.1	nM	CHEMBL_ACT_3664607
P02791	6.5	Potency	316.2	nM	CHEMBL_ACT_4499265
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_3913819
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_4739097
CYP1A2	5	AC50	10000	nM	CHEMBL_ACT_6059581

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).